Beckman Coulter

Alain Richard joins Specific Diagnostics as Head of Commercial Operations, EMEA

Wednesday, September 16, 2020 - 11:20pm

MOUNTAIN VIEW, Calif., Sept. 16, 2020 /PRNewswire-PRWeb/ -- Specific Diagnostics today announced the appointment of industry veteran Alain Richard to the position of Head of Commercial Operations, EMEA, ahead of its European market launch.

Key Points: 
  • MOUNTAIN VIEW, Calif., Sept. 16, 2020 /PRNewswire-PRWeb/ -- Specific Diagnostics today announced the appointment of industry veteran Alain Richard to the position of Head of Commercial Operations, EMEA, ahead of its European market launch.
  • Previously, as Vice President EMEA Mr. Richard helped build Iris Diagnostics' commercial business in Europe, where he was its first employee, to a $55M division of Iris before its acquisition by Danaher company Beckman Coulter in 2009.
  • Mr. Richard will play a similar role on the Specific leadership team, where he will be responsible for overseeing commercial operations in Europe.
  • "We are fortunate to have someone with Alain's knowledge and experience join our leadership team," said Dr. Paul A. Rhodes, CEO of Specific.

Beckman Coulter Launches SARS-CoV-2 IgM Antibody Test and will begin shipping to U.S. Diagnostics Labs

Monday, August 24, 2020 - 1:00pm

BREA, Calif., Aug. 24, 2020 /PRNewswire/ --Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay .

Key Points: 
  • BREA, Calif., Aug. 24, 2020 /PRNewswire/ --Beckman Coulter, a clinical diagnostics leader, today announced the launch of its Access SARS-CoV-2 Immunoglobulin M (IgM) assay .
  • The new IgM antibody test demonstrated 99.9% specificity against 1,400 negative samples and 98.3% sensitivity at 15-30 days post-symptom onset.
  • A positive IgM antibody test may help physicians identify some of these patients who received a false negative PCR result and should self-isolate until a follow up PCR test can be administered."
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

Beckman Coulter's Automated Blood Banking Analyzer Receives 510(k) FDA Clearance

Thursday, July 23, 2020 - 1:00pm

BREA, Calif., July23, 2020 /PRNewswire/ --Beckman Coultertoday announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA)for its PK7400 Automated Microplate System and the system's reagents have completed FDA approval.

Key Points: 
  • BREA, Calif., July23, 2020 /PRNewswire/ --Beckman Coultertoday announced that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA)for its PK7400 Automated Microplate System and the system's reagents have completed FDA approval.
  • According to the AABB (formerly the American Association of Blood Banks), an estimated 33,000 units of blood are needed each day to meet patient need.
  • However, the organization also stated, more than 4,000 blood donation events have been cancelled due to the COVID-19 pandemic.
  • Beckman Coulter, the stylized logo, and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

$232+ Million GAS Pharyngitis Diagnostics Industry Assessment 2019-2027 - Includes Profiles of Abbott Labs, BD, Beckman Coulter, bioMerieux, DiaSorin, and More - ResearchAndMarkets.com

Tuesday, June 23, 2020 - 1:09pm

The "GAS Pharyngitis Diagnostics - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "GAS Pharyngitis Diagnostics - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global GAS Pharyngitis Diagnostics market accounted for $169.88 million in 2019 and is expected to reach $232.5 million by 2027, growing at a CAGR of 4% during the forecast period.
  • Incidence and prevalence of gas pharyngitis infections are gradually growing across the globe and thereby driving the growth of the market.
  • Some of the key players profiled in the GAS Pharyngitis Diagnostics Market include Abbott Laboratories, BD, Beckman Coulter, Inc. (Danaher), bioMerieux SA, DiaSorin S.p.A., F. Hoffmann-La Roche Ltd, Meridian Bioscience, Inc., Quidel Corporation and Sekisui Diagnostics.

Global Market Outlook for the Coronavirus Diagnostics Market to 2027

Friday, June 19, 2020 - 7:15pm

DUBLIN, June 19, 2020 /PRNewswire/ -- The "Coronavirus Diagnostics - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, June 19, 2020 /PRNewswire/ -- The "Coronavirus Diagnostics - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Diagnostics market accounted for $4.64 billion in 2018 and is expected to reach $8.82 billion by 2027 growing at a CAGR of 7.4% during the forecast period.
  • Some of the key players profiled in the Coronavirus Diagnostics Market include Abbott, Beckman Coulter, Becton, Dickinson and Company, bioMerieux, Bio-Rad Laboratories, GSK Biologicals, Hologic, Lonza, Ortho-Clinical Diagnostics, PerkinElmer, Qiagen and Roche Diagnostics.
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
    Company profiling with detailed strategies, financials, and recent developments

2020 Coronavirus Diagnostics Market Analysis by Type, Time Duration, Application, End-User and Geography - ResearchAndMarkets.com

Friday, June 12, 2020 - 3:58pm

The "Coronavirus Diagnostics - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Coronavirus Diagnostics - Global Market Outlook (2018-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Coronavirus Diagnostics market accounted for $4.64 billion in 2018 and is expected to reach $8.82 billion by 2027 growing at a CAGR of 7.4% during the forecast period.
  • Some of the key players profiled in the Coronavirus Diagnostics Market include Abbott, Beckman Coulter, Becton, Dickinson and Company, bioMerieux, Bio-Rad Laboratories, GSK Biologicals, Hologic, Lonza, Ortho-Clinical Diagnostics, PerkinElmer, Qiagen and Roche Diagnostics.
  • Covers Market data for the years 2017, 2018, 2019, 2023 and 2027
    Company profiling with detailed strategies, financials, and recent developments

FDA Lists Beckman Coulter Life Sciences RNA Extraction Kit For Use In EUA-Authorized COVID-19 Test

Thursday, May 28, 2020 - 5:06pm

Beckman Coulter Life Sciences has remained committed to developing high-performing, scalable reagents for laboratories testing COVID-19 patient swab samples.

Key Points: 
  • Beckman Coulter Life Sciences has remained committed to developing high-performing, scalable reagents for laboratories testing COVID-19 patient swab samples.
  • "RNA extraction is essential today for reliable COVID-19 testing," said Thomas Marshall, Ph.D., Genomics R&D Leader, Beckman Coulter Life Sciences.
  • In March, Beckman Coulter Life Sciences published two demonstrated RNA extraction methods for viral samples.
  • Beckman Coulter Life Sciences is an operating company within Danaher Corporation's (NYSE: DHR) Life Sciences platform.

Global Multiplexed Diagnostics Market 2020-2024 | Evolving Opportunities with Agilent Technologies Inc. and Becton, Dickinson and Co. | Technavio

Thursday, March 5, 2020 - 8:30am

The global multiplexed diagnostics market is poised to grow by USD 9.35 billion during 2020-2024, progressing at a CAGR of over 15% during the forecast period.

Key Points: 
  • The global multiplexed diagnostics market is poised to grow by USD 9.35 billion during 2020-2024, progressing at a CAGR of over 15% during the forecast period.
  • In addition, technological advancements are anticipated to boost the growth of the multiplexed diagnostics market.
  • For instance, Beckman Coulter, involved in innovating complex biomedical testing, introduced GeXP Genetic Analysis System, which enables multiplexed diagnostic assays.
  • Major Five Multiplexed Diagnostics Market Companies:
    Agilent Technologies Inc. operates the business under various segments such as Life sciences and applied markets, Diagnostics and genomics, and Agilent CrossLab.

Beckman Coulter, 2020 - Performance, Capabilities, Goals & Strategies in the Global Diagnostics Industry - ResearchAndMarkets.com

Thursday, February 6, 2020 - 10:57am

The "Beckman Coulter 2020: Market Shares and Competitive Position by Product and Country - Performance, Capabilities, Goals and Strategies in the Global Diagnostics Industry" company profile has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Beckman Coulter 2020: Market Shares and Competitive Position by Product and Country - Performance, Capabilities, Goals and Strategies in the Global Diagnostics Industry" company profile has been added to ResearchAndMarkets.com's offering.
  • This unique market intelligence report from LeadingMarketResearch provides information not available from any other published source.
  • The report includes diagnostics sales and market share estimates by product and country for Beckman Coulter and its main competitors, as well as a profile of the company's diagnostics business.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005416/en/

Beckman Coulter's Access PCT Procalcitonin Assay receives U.S. FDA 510(k) clearance

Tuesday, January 28, 2020 - 1:00pm

BREA, Calif., Jan. 28, 2020 /PRNewswire/ -- Beckman Coulter, a global leader in clinical diagnostics, todayannounced that its Access PCT assay has received FDA 510(k) clearance and is now available for sale in the United States.

Key Points: 
  • BREA, Calif., Jan. 28, 2020 /PRNewswire/ -- Beckman Coulter, a global leader in clinical diagnostics, todayannounced that its Access PCT assay has received FDA 510(k) clearance and is now available for sale in the United States.
  • The Access PCT assay enables healthcare providers to integrate procalcitonin testing analysis into their routine sepsis workups on core laboratory analyzers, as a primary or reflex test programmed though Beckman Coulter's REMISOL Advance middleware.
  • Access PCT is available for use on Beckman Coulter's Access Family of Immunoassay Systems including the Access 2, UniCel DxI 600 and UniCel DxI 800.
  • For more information regarding the Access PCT assay or Beckman Coulter's full suite of solutions for sepsis diagnosis and management, www.BeckmanCoulter.com/Sepsis .